NOT KNOWN FACTS ABOUT AZELAPRAG AMGEN

The choice follows observations of liver transaminitis without having clinically significant symptoms, and with no distinct dose dependence, in a few people from the azelaprag arms of the STRIDES Phase two clinical demo for weight problems (backlink).Strong cytochrome P450 3A4 and/or P-glycoprotein inhibitors could warrant AMG 986 dose reduction an